Alumis (ALMS) vs Climb Bio (CLYM)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Climb Bio (CLYM) has outperformed Alumis (ALMS) over the past year, gaining 440.6% versus a loss of 45.8%. Climb Bio is the larger company by market cap ($539.8 million vs $514.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALMS | CLYM |
|---|---|---|
| Share price | $3.96 | $9.19 |
| Market cap | $514.09M | $539.80M |
| 1-day change | -8.55% | -0.97% |
| YTD return | -59.43% | +129.75% |
| 1-year return | -45.75% | +440.59% |
| 5-year return | — | -33.21% |
| EPS (TTM) | $-3.53 | $-0.81 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $24.05M | — |
| Net income (latest FY) | $-243.32M | $-59.85M |
| Operating margin | -1886.92% | — |
| Net margin | -1011.75% | — |
| 52-week high | $31.35 | $18.33 |
| 52-week low | $3.94 | $1.64 |
| Distance from 52-week high | -87.37% | -49.86% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +540.91% | +209.03% |
| Average volume | 2.87M | 1.38M |
| Shares outstanding | 129.82M | 58.74M |
| Employees | 251 | 28 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLYM has outperformed ALMS by 486.3 percentage points over the past year.
About Alumis
ALMS stock →Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 251 employees
About Climb Bio
CLYM stock →Climb Bio, Inc., a clinical-stage biotechnology company, focuses on developing therapies to address unmet needs for patients living with immune-mediated diseases. The company's lead product candidate is the budoprutug, an anti-CD19 monoclonal antibody for the treatment of B-cell mediated diseases.
Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees
ALMS vs CLYM FAQ
Which is bigger, Alumis or Climb Bio?
Climb Bio (CLYM) is larger, with a market capitalization of $539.80M compared with $514.09M for Alumis (ALMS).
Which stock has performed better over the past year, ALMS or CLYM?
CLYM returned +440.59% over the past 12 months, compared with -45.75% for ALMS (price return, excluding dividends). Past performance does not predict future results.
Are Alumis and Climb Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.